Live birth following early follicular phase oocyte collection and vitrified-warmed embryo transfer 8 days later.
A 30-year-old woman with premature ovarian insufficiency had two follicles measuring 17 mm and 14 mm on day 3 of her menstrual cycle. Serum oestradiol concentration was 210 pg/ml. Recombinant human chorionic gonadotrophin was given and 5 mg/day letrozole started orally. One metaphase II oocyte was collected 36 h later. A 4-cell embryo was vitrified on the second day after fertilization. Letrozole was stopped on cycle day 8 due to absence of any other visible antral follicles. Oestradiol valerate 6 mg/day was started and the endometrium was 9.2 mm on cycle day 11. The embryo was warmed and transferred on cycle day 13, the 8th day after oocyte retrieval. Luteal phase support with progesterone, oestradiol and low molecular weight heparin was started on the day of transfer and continued until the 10th gestational week. A healthy girl weighing 3200 g was born at term. Early follicular phase oocyte collection did not result in early opening of the implantation window. Apparently secretory transformation was not started until luteal phase support, enabling a cleavage stage embryo transferred 8 days later to implant. Either corpus luteum formation could be disrupted or the endometrium could remain unresponsive to progesterone during the early follicular phase.
Assisted Reproduction Unit, Department of Obstetrics and Gynaecology, Konak Hastanesi, Kocaeli, Turkey.
Safak
S
Hatırnaz
Assisted Reproduction Unit, Department of Obstetrics and Gynaecology, Konak Hastanesi, Kocaeli, Turkey.
Ebru
E
Hatırnaz
Deptartment of Obtetrics and Gynaecology, Koç University School of Medicine, Istanbul, Turkey. Electronic address: barisata@ku.edu.tr.
Baris
B
Ata
D000328:Adult; D004624:Embryo Transfer / Q000379:methods*; D004622:Embryo, Mammalian; D005260:Female; D005498:Follicular Phase; D006801:Humans; D007231:Infant, Newborn; D050498:Live Birth; D008183:Luteal Phase / Q000187:drug effects; D054315:Oocyte Retrieval / Q000379:methods*; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D011374:Progesterone / Q000627:therapeutic use; D058989:Vitrification
D011374:Progesterone
aromatase inhibitor; endometrial receptivity; implantation; menstrual cycle; premature ovarian insufficiency; random start stimulation